Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evgen Pharma ( (GB:TCF) ) just unveiled an announcement.
TheraCryf has reported positive top-line toxicology data for its lead Ox-1 blocker in its addiction programme, with dosing in the first species showing the drug is well tolerated at up to 100 times the anticipated human therapeutic dose. The company has also successfully scaled up manufacturing, producing more than 2kg of clinical-grade drug and filing a manufacturing patent that could extend commercial protection to 2046.
With clinical trial enabling work progressing ahead of plan, TheraCryf expects to complete remaining activities by the end of the third quarter of 2026 and submit an application for Phase 1 human trials that year. Management emphasises that reaching Phase 1 is a major value inflection point in a substance use disorder market worth over $70bn and in an active neuroscience deal-making environment, and notes it has already turned down an approach it considered undervalued while engaging with other potential partners.
Spark’s Take on TCF Stock
According to Spark, TipRanks’ AI Analyst, TCF is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and cash burn despite a debt-free balance sheet). Technicals are moderately supportive due to price strength versus moving averages, but the very overbought RSI raises near-term risk. Valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on TCF stock, click here.
More about Evgen Pharma
TheraCryf plc is a UK-based biotechnology company focused on developing new medicines for addiction and other neuropsychiatric disorders within the central nervous system field. Its lead asset is a novel orexin-1 receptor antagonist for treating addiction, including binge eating, alcohol and substance use disorders, alongside earlier-stage programmes in fatigue of brain origin and glioblastoma.
Average Trading Volume: 6,495,325
Technical Sentiment Signal: Sell
Current Market Cap: £4.73M
See more data about TCF stock on TipRanks’ Stock Analysis page.